ActivePhase 3ACTRN12610000837022

Efficacy and Safety of Alemtuzumab for prevention of graft rejection and preservation of renal function in patients receiving Kidney Transplant

A Randomised Controlled Trial of the Efficacy and Safety of Alemtuzumab (MABCAMPATH) for Prevention of Graft Rejection and Preservation of Renal Function in Patients Receiving Kidney Transplants

Sponsor

National University Hospital

Enrollment

63 participants

Start Date

Feb 8, 2011

Study Type

Interventional

Conditions

End stage kidney failure

Summary

The purpose of the study is to compare, following kidney transplantation, the safety and efficacy of alemtuzumab (MABCAMPATH) and low-dose tacrolimus (CAMPATH group) versus standard dose of tacrolimus with Azathioprine and Steroids (STANDARD group)

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study evaluates a medication called alemtuzumab for preventing organ rejection and protecting kidney function in people receiving their first kidney transplant. It is for adults aged 18 to 65 who are receiving a kidney from either a living or deceased donor.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

For CAMPATH Group, the intervention is administration of 2 doses of alemtuzumab 20 mg intravenously, 1st dose within 6 hours post anastomosis and 2nd dose 24 hours after 1st dose, followed by treatment with low-dose Tacrolimus (oral tablets twice daily for 3 years) adjusted to Trough levels of 5-7 ng/mL for duration of trial. Patients will be followed up for 3 years after transplantation surgery.

Locations(2)

Philippines

Singapore

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000837022